![Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial - Rodbard - 2013 - Diabetic Medicine - Wiley Online Library Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial - Rodbard - 2013 - Diabetic Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c53f588e-58c2-49e7-8a7e-c5f79645ea21/dme.2013.30.issue-11.cover.jpg)
Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial - Rodbard - 2013 - Diabetic Medicine - Wiley Online Library
![Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin | SpringerLink Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11095-012-0739-z/MediaObjects/11095_2012_739_Fig5_HTML.gif)
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin | SpringerLink
![Simulated insulin degludec (IDeg) concentration–time profiles at steady... | Download Scientific Diagram Simulated insulin degludec (IDeg) concentration–time profiles at steady... | Download Scientific Diagram](https://www.researchgate.net/profile/Hanne-Haahr/publication/265254952/figure/fig2/AS:202908701335553@1425388612351/Mechanism-of-protraction-of-insulin-degludec-IDeg-and-visualisation-of-IDeg-using_Q320.jpg)
Simulated insulin degludec (IDeg) concentration–time profiles at steady... | Download Scientific Diagram
![Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine - Virtual Meeting | EASD Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine - Virtual Meeting | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/287678/Slide3.jpg)
Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine - Virtual Meeting | EASD
![Frontiers | Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns | Endocrinology Frontiers | Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns | Endocrinology](https://www.frontiersin.org/files/Articles/616514/fendo-12-616514-HTML/image_m/fendo-12-616514-g001.jpg)
Frontiers | Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns | Endocrinology
![Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine - Virtual Meeting | EASD Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine - Virtual Meeting | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/287678/Slide1.jpg)
Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine - Virtual Meeting | EASD
![Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes – topic of research paper in Medical engineering. Download scholarly article PDF Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes – topic of research paper in Medical engineering. Download scholarly article PDF](https://cyberleninka.org/viewer_images/659761/f/1.png)
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes – topic of research paper in Medical engineering. Download scholarly article PDF
![CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML](https://www.mdpi.com/cimb/cimb-44-00059/article_deploy/html/images/cimb-44-00059-g007.png)
CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML
![Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function | Cardiovascular Diabetology | Full Text Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-016-0410-9/MediaObjects/12933_2016_410_Fig1_HTML.gif)
Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function | Cardiovascular Diabetology | Full Text
![Insulin analogues in type 1 diabetes mellitus: getting better all the time | Nature Reviews Endocrinology Insulin analogues in type 1 diabetes mellitus: getting better all the time | Nature Reviews Endocrinology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrendo.2017.39/MediaObjects/41574_2017_Article_BFnrendo201739_Fig1_HTML.jpg)
Insulin analogues in type 1 diabetes mellitus: getting better all the time | Nature Reviews Endocrinology
![Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2001013503/2003813987/gr1.gif)
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2
![CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML](https://www.mdpi.com/cimb/cimb-44-00059/article_deploy/html/images/cimb-44-00059-g002.png)
CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML
![PDF) Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase PDF) Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase](https://i1.rgstatic.net/publication/50374909_Insulin_degludec_an_ultra-long-acting_basal_insulin_once_a_day_or_three_times_a_week_versus_insulin_glargine_once_a_day_in_patients_with_type_2_diabetes_A_16-week_randomised_open-label_phase_2_trial/links/5d2cf61b299bf1547cb9cf76/largepreview.png)
PDF) Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase
![PDF) Insulin degludec: A novel ultra-acting basal insulin: Potential usefulness in hospitalized patients PDF) Insulin degludec: A novel ultra-acting basal insulin: Potential usefulness in hospitalized patients](https://i1.rgstatic.net/publication/299404568_Insulin_degludec_A_novel_ultra-acting_basal_insulin_Potential_usefulness_in_hospitalized_patients/links/57ebd2ac08aebb1961ff8cb7/largepreview.png)